Efficacy and safety of zuberitamab in the treatment of primary membranous nephropathy: an observational study
Zuberitamab may be a promising treatment option for PMN, demonstrating a high complete remission rate and sustained proteinuria reduction in this study. Large-scale prospective studies are warranted to confirm these findings.
Authors
- Xia Yang (ORCID: https://orcid.org/0000-0002-3971-038X)
- Sha Wang (ORCID: https://orcid.org/0000-0002-3945-2763)
- Li Zong
- Fang-yi Lv
- Ke Zhao
- Shan-kui Qian
Institutions
- Qilu Hospital of Shandong University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-12
- DOI
- https://doi.org/10.3389/fimmu.2025.1741564
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China